ArticleApplied health economics and health policy2018

Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work.

Gerard Harty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.